Synovo GmbH is a Tübingen based pharmaceutical discovery services company with a focus on inflammation and innate immunity providing services in: Medicinal Chemistry Pharmacology Cell Engineering Peptide Modification Synovo's main pharmacology activities are based on assays and models for the selection of drug candidates with improved properties of Absorption, Disposition, Metabolism and Elimination (ADME or DMPK). Synovo establishes these parameters using human derived cells, proteins and systems wherever feasible to ensure the relevance of its data to use in man. Synovo is engaged in projects in the fields of anti-inflammatory and immune suppressive drug optimization on behalf of clients from the pharmaceutical industry. Synovo is also working in partnership with public sector laboratories to improve its systems and extend its technologies to protein and nucleic acid drugs. Synovo is self-sustaining through its service business and it has always run profitably. The core of the services offering are pharmacological studies which it conducts mainly for biotech and mid-size companies. In addition, support functions like formulation chemistry and analytics enable more complex development studies. In parallel, Synovo uses its skills and facilities to conduct innovative research in collaboration with partners throughout the world. This has resulted in various drug candidates being developed for immune-oncology applications and more recently, inflammatory bowel disease and infection. Drug development is a long and costly process, so Synovo has also worked on projects which are easier to develop. Based in Tübingen, home of one of the most prestigious and best known Universities in Germany, Synovo GmbH benefits from access to cutting edge technology, highly skilled staff and a magnificent location over looking the Swabian Alps.